Related Experiment Video
Updated: Jun 19, 2026

A Large Animal Model for Acute Kidney Injury by Temporary Bilateral Renal Artery Occlusion
Published on: February 2, 2021
Vasopressin in chronic kidney disease: an elephant in the room?
1Mayo Clinic College of Medicine, Rochester, MN 55905, USA. torres.vicente@mayo.edu
Abstract:
Perico et al. report that a dual arginine vasopressin (AVP) V(2) and V(1a) receptor antagonist lowers blood pressure, proteinuria, and glomerulosclerosis in 5/6 nephrectomized rats, pointing to its potential value in the treatment of chronic kidney disease (CKD). AVP likely contributes to CKD progression by its effects on renal hemodynamics, blood pressure, and mesangial and/or epithelial cells, but the relative contributions of V(2) and V(1a) receptors and potential usefulness of V(2) and V(1a) receptor antagonists remain ill defined.
Related Concept Videos
Chronic Kidney Disease III: Interprofessional Care
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Chronic Kidney Disease IV: Nursing Management
Diabetes Insipidus I: Introduction
Acute Kidney Injury V: Interprofessional Care
Physiology of the Genitourinary System III: Urine Concentration and Dilution

